These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 32553459)

  • 21. Inhibition of PI3K pathway using BKM120 intensified the chemo-sensitivity of breast cancer cells to arsenic trioxide (ATO).
    Alipour F; Riyahi N; Safaroghli-Azar A; Sari S; Zandi Z; Bashash D
    Int J Biochem Cell Biol; 2019 Nov; 116():105615. PubMed ID: 31539632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biotransformation of arsenic trioxide by AS3MT favors eradication of acute promyelocytic leukemia: revealing the hidden facts.
    Maimaitiyiming Y; Zhu HH; Yang C; Naranmandura H
    Drug Metab Rev; 2020 Aug; 52(3):425-437. PubMed ID: 32677488
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of gamma-glutamyltransferase in acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
    Sui M; Wei H; Zhang Q; Xiu R; Shen X; Zhang Z; Zhou J
    Hematology; 2021 Dec; 26(1):58-64. PubMed ID: 33402059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Arsenic trioxide induces accumulation of cytotoxic levels of ceramide in acute promyelocytic leukemia and adult T-cell leukemia/lymphoma cells through de novo ceramide synthesis and inhibition of glucosylceramide synthase activity.
    Dbaibo GS; Kfoury Y; Darwiche N; Panjarian S; Kozhaya L; Nasr R; Abdallah M; Hermine O; El-Sabban M; de Thé H; Bazarbachi A
    Haematologica; 2007 Jun; 92(6):753-62. PubMed ID: 17550847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. miR-603 promotes cell proliferation and differentiation by targeting TrkB in acute promyelocytic leukemia.
    Li H; Hou J; Fu Y; Zhao Y; Liu J; Guo D; Lei R; Wu Y; Tang L; Fan S
    Ann Hematol; 2023 Dec; 102(12):3357-3367. PubMed ID: 37726492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Korean red ginseng extract induces proliferation to differentiation transition of human acute promyelocytic leukemia cells via MYC-SKP2-CDKN1B axis.
    Jo S; Lee H; Kim S; Lee CH; Chung H
    J Ethnopharmacol; 2013 Nov; 150(2):700-7. PubMed ID: 24095829
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Time course of arsenic species in red blood cells of acute promyelocytic leukemia (APL) patients treated with single agent arsenic trioxide.
    Guo M; Wang B; Liu S; Wang W; Gao C; Hu S; Fan S; Hai X; Zhou J
    Expert Rev Clin Pharmacol; 2019 Apr; 12(4):371-378. PubMed ID: 30795697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination Effect of Deferoxamine and Arsenic Trioxide on Viability and Vitality of APL Like Cell Line.
    Ghaffari K; Bayat A; Ghasemi A
    Ethiop J Health Sci; 2023 Jul; 33(4):703-710. PubMed ID: 38784214
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stimulation of Peroxisome Proliferator-Activated Receptor-Gamma (PPARγ) using Pioglitazone Decreases the Survival of Acute Promyelocytic Leukemia Cells through Up-Regulation of PTEN Expression.
    Esmaeili S; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Salari S; Gharehbaghian A; Hamidpour M; Bashash D
    Anticancer Agents Med Chem; 2021; 21(1):108-119. PubMed ID: 32807067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alteration in miRNA gene expression pattern in acute promyelocytic leukemia cell induced by arsenic trioxide: a possible mechanism to explain arsenic multi-target action.
    Ghaffari SH; Bashash D; Dizaji MZ; Ghavamzadeh A; Alimoghaddam K
    Tumour Biol; 2012 Feb; 33(1):157-72. PubMed ID: 22072212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Suppression of c-Myc using 10058-F4 exerts caspase-3-dependent apoptosis and intensifies the antileukemic effect of vincristine in pre-B acute lymphoblastic leukemia cells.
    Sheikh-Zeineddini N; Bashash D; Safaroghli-Azar A; Riyahi N; Shabestari RM; Janzamin E; Safa M
    J Cell Biochem; 2019 Aug; 120(8):14004-14016. PubMed ID: 30957273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia.
    Breccia M; Foà R
    Expert Rev Hematol; 2019 Feb; 12(2):81-87. PubMed ID: 30572725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Arsenic trioxide induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit PI3K/Akt signaling and thereby regulate p53 activation.
    Li Y; Qu X; Qu J; Zhang Y; Liu J; Teng Y; Hu X; Hou K; Liu Y
    Cancer Lett; 2009 Nov; 284(2):208-15. PubMed ID: 19457607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synergistic Effects of PI3K Inhibition on Arsenic Trioxide Cytotoxicity in Acute Promyelocytic Leukemia Cells: A New Portrait of Idelalisib as an Adjuvant Therapy.
    Dadashi M; Pourbagheri-Sigaroodi A; Anjam-Najmedini A; Bashash D
    Indian J Hematol Blood Transfus; 2023 Apr; 39(2):208-219. PubMed ID: 37006983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia.
    Ganesan S; Alex AA; Chendamarai E; Balasundaram N; Palani HK; David S; Kulkarni U; Aiyaz M; Mugasimangalam R; Korula A; Abraham A; Srivastava A; Padua RA; Chomienne C; George B; Balasubramanian P; Mathews V
    Leukemia; 2016 Nov; 30(11):2169-2178. PubMed ID: 27560113
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Arsenic trioxide decreases the amount and inhibits the function of regulatory T cells, which may contribute to its efficacy in the treatment of acute promyelocytic leukemia.
    Xu W; Li X; Quan L; Yao J; Mu G; Guo J; Wang Y
    Leuk Lymphoma; 2018 Mar; 59(3):650-659. PubMed ID: 28679299
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Toward Candidate Proteomic Biomarkers in Clinical Monitoring of Acute Promyelocytic Leukemia Treatment with Arsenic Trioxide.
    Cao F; Li X; Yang Y; Fang H; Qu H; Chang N; Ma Q; Cao W; Zhou J; Wang W
    OMICS; 2019 Feb; 23(2):119-130. PubMed ID: 30767729
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characteristics and clinical influence factors of arsenic species in plasma and their role of arsenic species as predictors for clinical efficacy in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide.
    Guo M; Zhou J; Fan S; Li L; Chen H; Lin L; Zhao Q; Wang X; Liu W; Wu Z; Hai X
    Expert Rev Clin Pharmacol; 2021 Apr; 14(4):503-512. PubMed ID: 33678104
    [No Abstract]   [Full Text] [Related]  

  • 39. Torsemide increases arsenic concentrations by inhibition of multidrug resistance protein 4 in arsenic trioxide treated acute promyelocytic leukemia patients.
    Lv J; Wu M; Pang C; Duan R; Zhang H; Tian S; Yang H; Hai X
    Biomed Pharmacother; 2023 Jul; 163():114858. PubMed ID: 37172335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. cAMP protects acute promyelocytic leukemia cells from arsenic trioxide-induced caspase-3 activation and apoptosis.
    Safa M; Mousavizadeh K; Noori S; Pourfathollah A; Zand H
    Eur J Pharmacol; 2014 Aug; 736():115-23. PubMed ID: 24815320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.